Pancreatic cancer is the 4th leading cause of cancer death in the United States. This is in large part due to the rapidly fatal course of this disease, as the vast majority of patients die within months of diagnosis and the five- year survival rate is less than 5%. Like all cancers, pancreatic cancer is a fundamentally genetic disease caused by inherited and acquired genetic mutations. Two genome-wide association studies of pancreatic cancer, PanScan I and PanScan II, have recently been completed. These studies have identified four promising regions involved in pancreatic cancer susceptibility: ABO rs505922 (P=4.3.10-6), two correlated SNPs on chromosome 13q22.1, rs9543325 (P=3.3.10-11) and rs9564966 (P=5.9.10-8), rs3790844 (P=2.4.10-10) on chromosome 1q32.1, and rs401681 (P=3.7.10-7) on 5p15.33. The goal of this project is to conduct fine-mapping and large-scale validation genotyping of the potential pancreatic cancer susceptibility variants identified in the recently completed PanScan I and PanScan II studies, in an independent set of 4,000 cases and 4,000 controls from over 10 studies. This will be the first well-powered large-scale replication of these findings. Joint-analysis of these data with the data from PanScanI and II will also be conducted. We will also determine known risk factors for pancreatic cancer including, cigarette smoking and diabetes modify these associations.
Genome-wide association studies (GWAS) are powerful tools to identify changes in DNA associated with diseases. These studies have identified many genes that play an important role in breast, prostate and colon cancers but the first of these studies have only recently been completed for pancreatic cancer. Before the findings of these studies can be translated into the patient setting, replication of the initial findings needs to be conducted to establish that changes in DNA are """"""""truly"""""""" associated with pancreatic cancer, not false findings. Furthermore, follow-up GWA studies also have the potential to identify novel associations. Therefore the goal of this study will be to validate the initial pancreatic cancer GWAS findings and identify novel DNA changes that may be associated with pancreatic cancer.
|Roberts, Nicholas J; Norris, Alexis L; Petersen, Gloria M et al. (2016) Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discov 6:166-75|
|Campa, Daniele; Rizzato, Cosmeri; Stolzenberg-Solomon, Rachael et al. (2015) TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Int J Cancer 137:2175-83|
|Childs, Erica J; Mocci, Evelina; Campa, Daniele et al. (2015) Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet 47:911-6|
|Tang, Hongwei; Wei, Peng; Duell, Eric J et al. (2014) Genes-environment interactions in obesity- and diabetes-associated pancreatic cancer: a GWAS data analysis. Cancer Epidemiol Biomarkers Prev 23:98-106|
|Roberts, Nicholas J; Klein, Alison P (2013) Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer. Cancer Lett 340:227-33|
|Klein, Alison P; LindstrÃ¶m, Sara; Mendelsohn, Julie B et al. (2013) An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. PLoS One 8:e72311|
|Wolfgang, Christopher L; Herman, Joseph M; Laheru, Daniel A et al. (2013) Recent progress in pancreatic cancer. CA Cancer J Clin 63:318-48|
|Klein, Alison P (2013) Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 13:66-74|
|Al-Sukhni, Wigdan; Joe, Sarah; Lionel, Anath C et al. (2012) Identification of germline genomic copy number variation in familial pancreatic cancer. Hum Genet 131:1481-94|